| Mrs Danielle Leigh Cheng, AGPCNP-BC | |
|
100 W Main St, Marion, MI 49665-9239 | |
| (231) 743-0150 | |
| (231) 743-0152 |
| Full Name | Mrs Danielle Leigh Cheng |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine - Geriatric Medicine |
| Location | 100 W Main St, Marion, Michigan |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225892458 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0300X | Internal Medicine - Geriatric Medicine | 4704307921 (Michigan) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Danielle Leigh Cheng, AGPCNP-BC Po Box 578, Marion, MI 49665-0578 Ph: (231) 743-0150 | Mrs Danielle Leigh Cheng, AGPCNP-BC 100 W Main St, Marion, MI 49665-9239 Ph: (231) 743-0150 |
News Archive
Research presented at the American Academy of Pain Medicine's 26th Annual Meeting provides early published data analyzing information gathered from California's prescription monitoring program, known as the Controlled Substances Utilization Review and Evaluation System (CURES). The analysis found a two-fold increase in the likelihood of individuals receiving opioids from multiple providers or "doctor shopping" when they were also being simultaneously prescribed a single additional class of a controlled substances, such as benzodiazepines or amphetamines.
The Ford Foundation today announced a $25 million effort to fight the disproportionate yet largely hidden impact of HIV/AIDS on marginalized communities in the United States.
Special RNA molecules called long non-coding RNAs (lncRNAs) are key controllers for maintaining immune health when fighting infection or preventing inflammatory disorders, according to research led by Jorge Henao-Mejia, MD, PhD, an assistant professor of Pathology and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania.
NeuroVive Pharmaceutical AB (publ) and A1M Pharma AB (publ) have announced that the two companies are initiating a research collaboration in mitochondrial medicine. The partnership is governed by a collaboration agreement signed on 21 March 2014.
Application of a technology currently used to disinfect food products may help to get around one of the most challenging problems in medicine today, the proliferation of bacteria resistant to antibiotics and other antimicrobial drugs.
› Verified 9 days ago